blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2506010

EP2506010 - VEGF polymorphisms and anti-angiogenesis therapy [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  22.04.2016
Database last updated on 23.04.2024
Most recent event   Tooltip06.10.2017Lapse of the patent in a contracting state
New state(s): CY, HU, MT, NL, SE
published on 08.11.2017  [2017/45]
Applicant(s)For all designated states
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080 / US
[2012/40]
Inventor(s)01 / Schneider, Bryan P
790 Foxboro Drive
Avon, IN Indiana 46123 / US
02 / Radovich, Milan
7116 Moon Court
Indianapolis, IN Indiana 46241 / US
03 / Sledge, George W.
6342 Dawson Lake Drive
Indianapolis, IN Indiana 46220 / US
 [2012/40]
Representative(s)Denison, Christopher Marcus
Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
[2015/25]
Former [2012/40]Denison, Christopher Marcus
Mewburn Ellis LLP 33 Gutter Lane London
EC2V 8AS / GB
Application number, filing date11179025.926.11.2008
[2012/40]
Priority number, dateUS20070991616P30.11.2007         Original published format: US 991616 P
US20080038699P21.03.2008         Original published format: US 38699 P
[2012/40]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2506010
Date:03.10.2012
Language:EN
[2012/40]
Type: A3 Search report 
No.:EP2506010
Date:09.01.2013
Language:EN
[2013/02]
Type: B1 Patent specification 
No.:EP2506010
Date:17.06.2015
Language:EN
[2015/25]
Search report(s)(Supplementary) European search report - dispatched on:EP07.12.2012
ClassificationIPC:G01N33/50
[2012/40]
CPC:
G01N33/574 (EP,KR,US); C12Q1/6883 (EP,CN,KR,US); A61P35/00 (EP);
G01N33/15 (KR); G01N33/6893 (EP,KR,US); C12Q1/6804 (RU);
C12Q1/6827 (RU); C12Q1/6844 (RU); C12Q1/6858 (RU);
C12Q1/686 (RU); C12Q1/6881 (RU); C12Q2531/113 (RU);
C12Q2561/101 (RU); C12Q2561/113 (RU); C12Q2600/106 (EP,CN,KR,US);
C12Q2600/118 (EP,CN,KR,US); C12Q2600/136 (RU); C12Q2600/142 (EP,CN,KR,US);
C12Q2600/156 (EP,CN,KR,RU,US); G01N2800/321 (EP,KR,US); G01N2800/50 (EP,KR,US);
G01N2800/52 (EP,KR,RU,US); G01N33/57415 (RU); G01N33/577 (RU) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2015/25]
Former [2012/40]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:VEGF-Polymorphismen und Anti-Angiogenesetherapie[2012/40]
English:VEGF polymorphisms and anti-angiogenesis therapy[2012/40]
French:Polymorphismes VEGF et thérapie anti-angiogenèse[2012/40]
Examination procedure09.05.2012Despatch of communication of loss of particular rights: Claims {1}
09.07.2013Amendment by applicant (claims and/or description)
09.07.2013Examination requested  [2013/33]
02.07.2014Despatch of a communication from the examining division (Time limit: M04)
11.11.2014Reply to a communication from the examining division
09.01.2015Communication of intention to grant the patent
06.05.2015Receipt of the translation of the claim(s)
07.05.2015Fee for grant paid
07.05.2015Fee for publishing/printing paid
Parent application(s)   TooltipEP08857392.8  / EP2220492
Divisional application(s)EP15168854.6   Application withdrawn  : 29.04.2016
Opposition(s)18.03.2016No opposition filed within time limit [2016/21]
Request for further processing for:Loss of rights: Claims
05.07.2012Request for further processing filed
05.07.2012Full payment received (date of receipt of payment)
Request granted
17.07.2012Decision despatched
Fees paidRenewal fee
14.09.2011Renewal fee patent year 03
14.09.2011Renewal fee patent year 04
13.11.2012Renewal fee patent year 05
07.11.2013Renewal fee patent year 06
07.11.2014Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU26.11.2008
AT17.06.2015
BE17.06.2015
CY17.06.2015
CZ17.06.2015
DK17.06.2015
EE17.06.2015
FI17.06.2015
HR17.06.2015
LT17.06.2015
LV17.06.2015
MC17.06.2015
MT17.06.2015
NL17.06.2015
PL17.06.2015
RO17.06.2015
SE17.06.2015
SI17.06.2015
SK17.06.2015
BG17.09.2015
NO17.09.2015
GR18.09.2015
IS17.10.2015
PT19.10.2015
IE26.11.2015
LU26.11.2015
[2017/39]
Former [2017/03]AT17.06.2015
BE17.06.2015
CZ17.06.2015
DK17.06.2015
EE17.06.2015
FI17.06.2015
HR17.06.2015
LT17.06.2015
LV17.06.2015
MC17.06.2015
PL17.06.2015
RO17.06.2015
SI17.06.2015
SK17.06.2015
BG17.09.2015
NO17.09.2015
GR18.09.2015
IS17.10.2015
PT19.10.2015
IE26.11.2015
LU26.11.2015
Former [2016/45]AT17.06.2015
CZ17.06.2015
DK17.06.2015
EE17.06.2015
FI17.06.2015
HR17.06.2015
LT17.06.2015
LV17.06.2015
MC17.06.2015
PL17.06.2015
RO17.06.2015
SI17.06.2015
SK17.06.2015
BG17.09.2015
NO17.09.2015
GR18.09.2015
IS17.10.2015
PT19.10.2015
IE26.11.2015
LU26.11.2015
Former [2016/36]AT17.06.2015
CZ17.06.2015
DK17.06.2015
EE17.06.2015
FI17.06.2015
HR17.06.2015
LT17.06.2015
LV17.06.2015
MC17.06.2015
PL17.06.2015
RO17.06.2015
SI17.06.2015
SK17.06.2015
BG17.09.2015
NO17.09.2015
GR18.09.2015
IS17.10.2015
PT19.10.2015
LU26.11.2015
Former [2016/31]AT17.06.2015
CZ17.06.2015
DK17.06.2015
EE17.06.2015
FI17.06.2015
HR17.06.2015
LT17.06.2015
LV17.06.2015
MC17.06.2015
PL17.06.2015
RO17.06.2015
SK17.06.2015
BG17.09.2015
NO17.09.2015
GR18.09.2015
IS17.10.2015
PT19.10.2015
LU26.11.2015
Former [2016/28]AT17.06.2015
CZ17.06.2015
DK17.06.2015
EE17.06.2015
FI17.06.2015
HR17.06.2015
LT17.06.2015
LV17.06.2015
MC17.06.2015
PL17.06.2015
RO17.06.2015
SK17.06.2015
BG17.09.2015
NO17.09.2015
GR18.09.2015
IS17.10.2015
PT19.10.2015
Former [2016/20]AT17.06.2015
CZ17.06.2015
DK17.06.2015
EE17.06.2015
FI17.06.2015
HR17.06.2015
LT17.06.2015
LV17.06.2015
PL17.06.2015
RO17.06.2015
SK17.06.2015
BG17.09.2015
NO17.09.2015
GR18.09.2015
IS17.10.2015
PT19.10.2015
Former [2016/11]AT17.06.2015
CZ17.06.2015
EE17.06.2015
FI17.06.2015
HR17.06.2015
LT17.06.2015
LV17.06.2015
PL17.06.2015
RO17.06.2015
SK17.06.2015
BG17.09.2015
NO17.09.2015
GR18.09.2015
IS17.10.2015
PT19.10.2015
Former [2016/10]CZ17.06.2015
EE17.06.2015
FI17.06.2015
HR17.06.2015
LT17.06.2015
LV17.06.2015
PL17.06.2015
RO17.06.2015
SK17.06.2015
BG17.09.2015
NO17.09.2015
GR18.09.2015
IS17.10.2015
PT19.10.2015
Former [2016/09]EE17.06.2015
FI17.06.2015
HR17.06.2015
LT17.06.2015
LV17.06.2015
BG17.09.2015
NO17.09.2015
GR18.09.2015
Former [2015/50]FI17.06.2015
HR17.06.2015
LT17.06.2015
LV17.06.2015
BG17.09.2015
NO17.09.2015
GR18.09.2015
Former [2015/49]FI17.06.2015
HR17.06.2015
LT17.06.2015
LV17.06.2015
NO17.09.2015
GR18.09.2015
Documents cited:Search[A]WO2006086544  (REGENERON PHARMA [US], et al) [A] 1-12 * the whole document *;
 [A]WO2007022101  (REGENERON PHARMA [US], et al) [A] 1-12 * the whole document *;
 [A]US2007207486  (LENZ HEINZ-JOSEF [US]) [A] 1-12 * abstract *;
 [XA]  - HAN S W ET AL, VEGF gene polymorphisms and susceptibility to rheumatoid arthritis, RHEUMATOLOGY (OXFORD), VOL. 43, NR. 9, PAGE(S) 1173-1177, (200409), ISSN 1462-0324, XP002681348 [X] 11,12 * page 1174; table 1 * [A] 1-10

DOI:   http://dx.doi.org/10.1093/RHEUMATOLOGY/KEH281
 [A]  - KOUKOURAKIS M I ET AL, "VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer", LUNG CANCER, ELSEVIER, AMSTERDAM, NL, (20041201), vol. 46, no. 3, doi:10.1016/J.LUNGCAN.2004.04.037, ISSN 0169-5002, pages 293 - 298, XP004638802 [A] 1-12 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.lungcan.2004.04.037
 [XP]  - SCHNEIDER BRYAN P ET AL, "Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 1 OCT 2008, (20081001), vol. 26, no. 28, ISSN 1527-7755, pages 4672 - 4678, XP009111528 [XP] 1-12 * the whole document *
by applicantUS4656127
 US4816567
 WO9102087
 US4998617
 WO9215712
 US5176996
 US5210015
 US5256775
 US5264564
 US5858659
 US5952172
 US5968740
 US6018041
 US6025136
 US6455249
    - FERRARA, DAVIS-SMYTH, ENDOCRINE REV., (1997), vol. 18, pages 4 - 25
    - FERRARA, J. J\ÆOL. MED., (1999), vol. 77, pages 527 - 543
    - PRESTA ET AL., CANCER RES., (1997), vol. 57, pages 4593 - 4599
    - SCHNEIDER ET AL., BREAST CANCER RESEARCH AND TREATMENT, (2008), vol. 111, pages 157 - 63
    - Methods in Enzymology, ACADEMIC PRESS, INC.
    - LEUNG ET AL., SCIENCE, (1989), vol. 246, page 1306
    - HOUCK ET AL., MOL. ENDOCRIN., (1991), vol. 5, page 1806
    - KOHLER ET AL., NATURE, (1975), vol. 256, page 495
    - CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628
    - MARKS ET AL., J. MO/. BIOL., (1991), vol. 222, pages 581 - 597
    - HE ET AL., ADV. EXP. MED. BIOL., (2007), vol. 593, pages 117 - 133
    - HELLER, ANNU. REV. BIOMED. ENG., (2002), vol. 4, pages 129 - 153
    - CRONIN ET AL., HUMAN MUTATION, (1996), vol. 7, page 244
    - MYERS ET AL., SCIENCE, (1985), vol. 230, page 1242
    - COTTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, page 4397
    - SALEEBA ET AL., METH. ENZYMOL., (1992), vol. 217, pages 286 - 295
    - ORITA ET AL., PROC NATL. ACAD. SCI USA, (1989), vol. 86, page 2766
    - COTTON, MUTAT. RES., (1993), vol. 285, pages 125 - 144
    - HAYASHI, GENET. ANAL. TECH. APPL., (1992), vol. 9, pages 73 - 79
    - KEEN ET AL., TRENDS GENET., (1991), vol. 7, page 5
    - MYERS ET AL., NATURE, (1985), page 313495
    - ROSENBAUM, REISSNER, BIOPHY,S. CHEM., (1987), vol. 265, page 1275
    - SAIKI ET AL., NATURE, (1986), vol. 324, page 163
    - SAIKI ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, page 6230
    - GIBBS ET AL., NUCL. ACIDS RES., (1989), vol. 17, pages 2437 - 2448
    - PROSSNER, TIBTECH, (1993), vol. 11, page 238
    - NEWTON ET AL., NUCL. ACIDS RES., (1989), vol. 17, page 2503
    - GASPARINI ET AL., MOL. CELL. PROBES, (1992), vol. 6, page 1
    - LARIDEGREN, U. ET AL., SCIENCE, (1988), vol. 241, pages 1077 - 1080
    - NICKERSON, D. A. ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 8923 - 8927
    - KOMHER, J. S. ET AL., NUCL. ACIDS. RES., (1989), vol. 17, pages 7779 - 7784
    - SOKOLOV, B. P., NUCL. ACIDS RES., (1990), vol. 18, page 3671
    - SYVANEN, A.-C. ET AL., GENOMICS, (1990), vol. 8, pages 684 - 692
    - KUPPUSWAMY, M. N. ET AL., PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, pages 1143 - 1147
    - PREZANT, T. R. ET AL., HUM. MUTAT., (1992), vol. 1, pages 159 - 164
    - UGOZZOLI, L. ET AL., GATA, (1992), vol. 9, pages 107 - 112
    - NYREN, P. ET AL., ANAL. BIOCHEM., (1993), vol. 208, pages 171 - 175
    - HOLLAND ET AL., PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, pages 7276 - 7280
    - KELLEY, S. O. ET AL., NUCL. ACIDS RES., (1999), vol. 27, pages 4830 - 4837
 US19990610386
 US20070991616
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.